Diaxonhit Stock Euronext Paris
Equities
FR0004054427
Biotechnology & Medical Research
Sales 2023 * | 131M 140M | Sales 2024 * | 138M 148M | Capitalization | 148M 158M |
---|---|---|---|---|---|
Net income 2023 * | 6M 6.42M | Net income 2024 * | 9M 9.62M | EV / Sales 2023 * | 1.2 x |
Net Debt 2023 * | 8.8M 9.41M | Net cash position 2024 * | 9.9M 10.59M | EV / Sales 2024 * | 1 x |
P/E ratio 2023 * |
33.6
x | P/E ratio 2024 * |
15.2
x | Employees | - |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 59.14% |
Managers | Title | Age | Since |
---|---|---|---|
Denis Fortier
CEO | Chief Executive Officer | - | 17-06-18 |
Director of Finance/CFO | 43 | 22-09-30 | |
Cathie Marsais
COO | Chief Operating Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Denis Fortier
CEO | Chief Executive Officer | - | 17-06-18 |
Director/Board Member | 68 | 09-11-03 | |
Director/Board Member | 67 | 17-06-14 |
1st Jan change | Capi. | |
---|---|---|
+1.88% | 42.59B | |
+8.51% | 40.65B | |
+49.22% | 40.57B | |
-12.36% | 26.77B | |
+9.06% | 24.81B | |
-24.42% | 18.17B | |
+28.89% | 12.05B | |
-2.75% | 11.7B | |
+7.09% | 11.1B |